info@marketresearchfuture.com   📞 +1 (855) 661-4441(US)   📞 +44 1720 412 167(UK)   📞 +91 2269738890(APAC)
Certified Global Research Member
Isomar 1 Iso 1
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

UK Gastritis Treatment Market Research Report By Diagnosis (Blood Test, Endoscopy), By Treatment (Acid Blocking Medicines, Antibiotics), By Drug Distribution Channel (Retail Pharmacy), and By End-User (Hospitals, Clinics)- Forecast to 2035


ID: MRFR/HC/54215-HCR | 200 Pages | Author: Rahul Gotadki| July 2025

UK Gastritis Treatment Market Overview


As per MRFR analysis, the UK Gastritis Treatment Market Size was estimated at 2.98 (USD Million) in 2023.The UK Gastritis Treatment Market is expected to grow from 3.4(USD Million) in 2024 to 12.8 (USD Million) by 2035. The UK Gastritis Treatment Market CAGR (growth rate) is expected to be around 12.806% during the forecast period (2025 - 2035).


Key UK Gastritis Treatment Market Trends Highlighted


Numerous factors are driving noticeable changes in the UK Gastritis Treatment Market. The rising incidence of gastritis and other gastrointestinal problems in the UK population is one of the main factors propelling the market. This increase is largely caused by factors including poor diet, high levels of stress, and the use of non-steroidal anti-inflammatory medicines (NSAIDs).


According to National Health Service (NHS) data, people are becoming more aware of and cognizant of the signs of gastritis, which encourages them to seek immediate medical attention and fuels market expansion. Adoption of cutting-edge treatment alternatives like tailored medicine and sophisticated endoscopic procedures is one of the opportunities in the UK Gastritis Treatment Market.


Improved diagnostic methods and treatments that target the root causes of gastritis, such as eliminating Helicobacter pylori, present opportunities for medical professionals and pharmaceutical firms to investigate. Furthermore, the increased focus on healthcare prevention offers opportunities for patient education programs that can result in early diagnosis and treatment.


Recent trends indicate a move toward integrated care approaches, in which medical professionals place more emphasis on nutritional advice and lifestyle changes in addition to pharmaceutical therapies. In the UK, this all-encompassing strategy is becoming more popular as medical practitioners realize how crucial patient involvement is to successfully treating gastritis.


Additionally, telemedicine has grown in popularity since it enables patients to contact experts from the convenience of their homes, perhaps improving treatment compliance. Overall, changing patient needs and cutting-edge medical advancements are creating a dynamic landscape in the UK Gastritis Treatment Market.


UK Gastritis Treatment Market size


Source: Primary Research, Secondary Research, MRFR Database and Analyst Review


UK Gastritis Treatment Market Drivers


Increasing Incidence of Gastritis


The prevalence of gastritis in the UK has seen a notable rise due to lifestyle changes, dietary habits, and the effects of stress. Studies suggest that approximately 10% to 20% of the UK population experiences gastritis, leading to an increased demand for effective treatment options.


Organizations such as the National Health Service (NHS) have reported a significant rise in outpatient visits related to gastritis conditions, reflecting the growing burden on healthcare systems.


The urgency for innovative treatment solutions in the UK Gastritis Treatment Market is further underscored by the increasing focus on health and wellness among the population, prompting governments and private entities to invest in Research and Development (R&D) for new therapeutic modalities.


A comprehensive strategy to manage gastritis is critical, considering the potential for chronic complications that can arise from untreated cases. These developments create a favorable environment for the overall growth and enhancement of treatment availability in the UK.


Growth in Healthcare Expenditure


The UK's national healthcare spending continues to rise, providing more resources for the treatment of various health conditions, including gastritis. In the past few years, the government has increased health expenditure by more than 4% annually, resulting in a more robust healthcare system that can accommodate new treatments and technologies for gastric disorders.


Organizations like the Department of Health and Social Care are actively working on initiatives to enhance patient outcomes, which directly support advancements in the UK Gastritis Treatment Market. This increase in funding not only promotes R&D but also enables healthcare providers to improve access to effective therapies, thereby supporting growth in the gastritis treatment sector.


Technological Advancements in Treatment Options


Recent innovations in medical technology, particularly in endoscopy and imaging techniques, have led to improved diagnosis and treatment of gastritis in the UK. Developments in minimally invasive procedures and new pharmacological treatments have revolutionized how gastritis is managed, improving patient outcomes significantly.


The NHS has integrated advanced diagnostics into routine care, leading to the early identification of gastritis and personalization of treatment protocols.


Furthermore, collaborations with organizations focused on improving gastrointestinal health have spurred Research and Development (R&D) projects that aim to create more effective treatment options. The continuous evolution of these technologies is a pivotal driver for the growth of the UK Gastritis Treatment Market, as they enable clinicians to provide superior care to patients.


Awareness and Education Campaigns


Public health initiatives aimed at raising awareness about gastrointestinal health, including gastritis, are gaining momentum across the UK. With organizations like the British Society of Gastroenterology leading these educational campaigns, the public is becoming more informed about the symptoms, risks, and treatments associated with gastritis.


Recent surveys indicate that health literacy regarding gastritis has improved by 15% over the last five years, according to publications from national health agencies.


This heightened awareness leads to increased patient engagement in seeking treatment, which directly impacts the growth of the UK Gastritis Treatment Market. As more individuals seek appropriate medical advice and care for their symptoms, the demand for effective treatment solutions is likely to escalate.


UK Gastritis Treatment Market Segment Insights


Gastritis Treatment Market Diagnosis Insights


The Diagnosis segment within the UK Gastritis Treatment Market is vital for identifying and managing gastritis effectively. The segment's growth is propelled by rising awareness of gastrointestinal disorders and the increasing prevalence of gastritis in the population.


As the healthcare landscape evolves, so do the methodologies for diagnosing gastritis, with Blood Test and Endoscopy emerging as prominent methods. Blood Tests are instrumental in assessing the presence of specific antibodies that indicate gastritis, making it a common first step in diagnosis.


Meanwhile, Endoscopy remains a crucial procedure, providing direct visualization of the gastric mucosa and enabling targeted biopsies when necessary, which facilitates accurate diagnoses. Both methods are supported by advancements in medical technology, leading to increased accuracy and efficiency in diagnosis.


The UK's robust healthcare system, complemented by government initiatives aimed at improving digestive health, further enhances the growth prospects of the Diagnosis segment. Additionally, rising healthcare expenditures and a greater emphasis on preventive health measures contribute to market growth.


Challenges such as the high costs associated with advanced diagnostic tests and limited accessibility in rural areas could pose hurdles. However, ongoing research and technological advancements are expected to mitigate these challenges, presenting numerous opportunities for innovation in diagnostic methodologies.


Overall, the Diagnosis segment is positioned to play a pivotal role in shaping the future of gastritis management in the UK, supported by growing public health campaigns aimed at increasing awareness and improving patient outcomes.


UK Gastritis Treatment Market Segment


Source: Primary Research, Secondary Research, MRFR Database and Analyst Review


Gastritis Treatment Market Treatment Insights


The Treatment segment of the UK Gastritis Treatment Market is pivotal in addressing the rising prevalence of gastritis among the population, which has been influenced by factors such as poor dietary habits and increased use of non-steroidal anti-inflammatory drugs.


Within this segment, Acid Blocking Medicines play a crucial role in managing symptoms by reducing gastric acidity, thus promoting mucosal healing and offering relief from pain. The growing consumer awareness regarding health and nutrition drives the demand for these medications significantly.


In parallel, Antibiotics are essential in the treatment of gastritis caused by bacterial infections, particularly Helicobacter pylori, which is known to exacerbate the condition. The relationship between rising antibiotic resistance and the focus on effective treatment strategies has underscored their importance in the UK gastritis landscape.


Additionally, as the UK continues to enhance healthcare accessibility, the market is expected to experience an increase in treatment options, allowing patients a greater choice in managing their condition effectively.


The integration of advanced therapeutic approaches alongside traditional treatments, supported by ongoing Research and Development initiatives, is likely to bolster the industry's growth, reflecting the dynamic nature of the UK Gastritis Treatment Market.


Gastritis Treatment Market Drug Distribution Channel Insights


The Drug Distribution Channel segment within the UK Gastritis Treatment Market plays a crucial role in ensuring the accessibility and availability of treatments. Retail Pharmacy emerges as a key player in this segment, providing patients with direct access to medications for gastritis.


The convenience of retail pharmacies, often located within communities, facilitates quick procurement for patients, thereby improving adherence to treatment regimens. In recent years, there has been a noticeable trend where retail pharmacies are enhancing their services by offering consultations and health screenings, ensuring patients receive comprehensive care related to gastritis management.


This segment significantly contributes to the market revenue through reliable supply chains and a broader range of products. Moreover, as the prevalence of gastritis continues to rise in the UK, driven by factors such as lifestyle changes and an increasing focus on gastrointestinal health, the demand within this channel is expected to grow steadily.


Retail pharmacies are also adapting to digital trends by incorporating online services, which helps meet the needs of consumers preferring remote access to their prescriptions. The synergy between healthcare providers and retail pharmacies enhances patient outcomes, making this distribution channel a significant component of the UK Gastritis Treatment Market dynamics.


Gastritis Treatment Market End-User Insights


The UK Gastritis Treatment Market is extensively segmented by End-User, prominently featuring hospitals and clinics, which play a crucial role in the delivery of gastritis care. Hospitals serve as primary facilities equipped with advanced technology and specialized staff, thus facilitating comprehensive treatment plans for patients suffering from gastritis.


On the other hand, clinics provide a more accessible avenue for patients to seek care, often reflecting a growing preference for outpatient services. As the demand for gastritis treatment rises, factors such as increasing awareness about gastrointestinal health and the impact of dietary choices significantly drive traffic to these healthcare facilities.


The trend towards preventive care and early diagnosis further amplifies the importance of hospitals and clinics in managing gastritis. Additionally, with the UK's rising population and the corresponding healthcare demands, these establishments are likely to see a majority of patient inflow, capturing significant market shares within the overall landscape of the UK Gastritis Treatment Market.


Overall, this segment is vital for ensuring that patients receive timely and effective treatment, contributing to improved patient outcomes and tackling healthcare challenges related to gastritis.


UK Gastritis Treatment Market Key Players and Competitive Insights


The UK Gastritis Treatment Market demonstrates a nuanced landscape characterized by a range of pharmaceutical companies that offer diverse treatment options for patients suffering from gastritis. As gastritis continues to be a prevalent gastrointestinal condition impacting a significant portion of the population, competition within this market is escalating.


Various players are vying for market share by developing innovative medications, enhancing patient outcomes, and expanding their distribution networks. As healthcare advancements continue to evolve, pharmaceutical firms are actively investing in research and development to provide more effective solutions while addressing the unique needs of patients in the UK.


This competitive dynamic is further intensified by an increasing focus on patient-centric approaches, regulatory challenges, and the need for comprehensive therapeutic solutions, all of which are shaping the strategic landscape of the gastritis treatment market.


Pfizer holds a prominent position in the UK Gastritis Treatment Market, benefiting from its extensive experience in the pharmaceutical industry and a broad portfolio of gastrointestinal medications. The company leverages its strong research capabilities to innovate treatments that can effectively manage gastritis symptoms, focusing on both short-term relief and long-term efficacy.


One of Pfizer's key strengths lies in its established brand recognition and trust among healthcare providers and patients alike, allowing it to maintain a competitive edge in the market. Pfizer's significant investment in marketing and outreach efforts has further bolstered its position, enabling the company to reach a wider audience and effectively communicate the benefits of its products.


AbbVie is another key player in the UK Gastritis Treatment Market, known for its strong focus on research and development, particularly in the realm of autoimmune and gastrointestinal disorders. The company has developed a range of effective treatments that address gastritis-related symptoms, focusing on both symptom management and underlying causes.


AbbVie's strengths include a robust pipeline of innovative therapies and recent mergers and acquisitions that have expanded its capabilities in the gastrointestinal market. These strategic moves have solidified its presence in the UK, allowing AbbVie to enhance its product offerings and cater to the evolving demands of healthcare providers and patients.


By emphasizing quality, efficacy, and patient safety, AbbVie remains a formidable competitor in the gastritis treatment landscape while continuing to explore new opportunities for growth and differentiation in the market.


Key Companies in the UK Gastritis Treatment Market Include:



  • Pfizer

  • AbbVie

  • Merck

  • GlaxoSmithKline

  • Roche

  • Bristol-Myers Squibb

  • Novartis

  • Eli Lilly

  • Bayer

  • Sanofi

  • Takeda

  • Amgen

  • Johnson & Johnson

  • AstraZeneca


UK Gastritis Treatment Market Developments


The UK Gastritis Treatment Market has witnessed several developments recently, with companies like Pfizer, AbbVie, and Merck focusing on innovative therapies to enhance patient outcomes. Current affairs highlight a growing emphasis on personalized medicine and advancements in drug formulations that effectively address chronic gastritis.


Notably, in August 2023, Johnson and Johnson expanded its gastrointestinal portfolio by acquiring a novel treatment for gastritis, strengthening its position in the market. Similarly, AstraZeneca has been engaged in Research and Development initiatives aimed at optimizing treatments for gastritis associated with Helicobacter pylori.


In the last two years, Novartis and GlaxoSmithKline have launched new medications targeting inflammation and mucosal repair in gastritis patients, contributing to market growth. The overall valuation of the UK Gastritis Treatment Market has been positively impacted by these innovations, as evidenced by a recent surge in investment from leading pharmaceutical firms.


Furthermore, increasing awareness and diagnosis of gastritis conditions within the healthcare sector are helping to drive demand for effective treatments. These elements represent a dynamic landscape that continues to evolve, reflecting both market needs and the commitment of key players to improve patient care in the UK.


UK Gastritis Treatment Market Segmentation Insights


Gastritis Treatment Market Diagnosis Outlook



  • Blood Test

  • Endoscopy


Gastritis Treatment Market Treatment Outlook



  • Acid Blocking Medicines

  • Antibiotics


Gastritis Treatment Market Drug Distribution Channel Outlook



  • Retail Pharmacy


Gastritis Treatment Market End-User Outlook



  • Hospitals

  • Clinics

 
Report Attribute/Metric Source: Details
MARKET SIZE 2023 2.98(USD Million)
MARKET SIZE 2024 3.4(USD Million)
MARKET SIZE 2035 12.8(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR) 12.806% (2025 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
MARKET FORECAST PERIOD 2025 - 2035
HISTORICAL DATA 2019 - 2024
MARKET FORECAST UNITS USD Million
KEY COMPANIES PROFILED Pfizer, AbbVie, Merck, GlaxoSmithKline, Roche, BristolMyers Squibb, Novartis, Eli Lilly, Bayer, Sanofi, Takeda, Amgen, Johnson & Johnson, AstraZeneca
SEGMENTS COVERED Diagnosis, Treatment, Drug Distribution Channel, End-User
KEY MARKET OPPORTUNITIES Increased prevalence of gastritis, Rising demand for personalized treatments, Growth in telehealth services, Advanced drug development, Expansion of dietary supplements market
KEY MARKET DYNAMICS rising prevalence of gastritis, increasing healthcare expenditure, advancements in treatment options, growing awareness of digestive health, rising demand for personalized medicine
COUNTRIES COVERED UK


Frequently Asked Questions (FAQ) :

The UK Gastritis Treatment Market is expected to be valued at 3.4 million USD in 2024.

By 2035, the UK Gastritis Treatment Market is projected to reach a value of 12.8 million USD.

The market is expected to grow at a CAGR of 12.806 percent from 2025 to 2035.

The market is divided into two main diagnostic methods: Blood Test and Endoscopy.

Blood Test diagnostics in the UK Gastritis Treatment Market is valued at 1.5 million USD in 2024.

The Endoscopy diagnostics segment is valued at 1.9 million USD in 2024.

By 2035, Blood Test diagnostics are expected to grow to 5.8 million USD.

The market value for Endoscopy diagnostics is projected to be 7.0 million USD by 2035.

Major players in the market include Pfizer, AbbVie, Merck, GlaxoSmithKline, and Roche.

Emerging trends and an increasing focus on effective treatment options present significant growth opportunities in the market.

Comments

Leading companies partner with us for data-driven Insights.

clients

Kindly complete the form below to receive a free sample of this Report

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.
report-img